Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1960 1
1962 1
1963 1
1965 1
1969 2
1970 2
1971 1
1972 1
1974 1
1975 3
1984 1
1985 3
1986 2
1987 2
1988 1
1991 1
1992 1
1993 1
1995 1
2005 1
2006 2
2009 3
2010 2
2011 1
2012 3
2013 2
2015 3
2016 3
2017 2
2018 2
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

52 results
Results by year
Filters applied: . Clear all
Page 1
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Andtbacka RH, et al. Among authors: amatruda t. J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26. J Clin Oncol. 2015. PMID: 26014293 Clinical Trial.
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, Amatruda T, Zager JS, Cranmer L, Hsueh E, Chen L, Shilkrut M, Kaufman HL. Andtbacka RH, et al. Among authors: amatruda t. Ann Surg Oncol. 2016 Dec;23(13):4169-4177. doi: 10.1245/s10434-016-5286-0. Epub 2016 Jun 24. Ann Surg Oncol. 2016. PMID: 27342831 Free PMC article. Clinical Trial.
Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
Andtbacka RHI, Amatruda T, Nemunaitis J, Zager JS, Walker J, Chesney JA, Liu K, Hsu CP, Pickett CA, Mehnert JM. Andtbacka RHI, et al. Among authors: amatruda t. EBioMedicine. 2019 Sep;47:89-97. doi: 10.1016/j.ebiom.2019.07.066. Epub 2019 Aug 10. EBioMedicine. 2019. PMID: 31409575 Free PMC article. Clinical Trial.
Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1).
Perez MC, Zager JS, Amatruda T, Conry R, Ariyan C, Desai A, Kirkwood JM, Treichel S, Cohan D, Raskin L. Perez MC, et al. Among authors: amatruda t. Melanoma Manag. 2019 Jul 3;6(2):MMT19. doi: 10.2217/mmt-2019-0012. Melanoma Manag. 2019. PMID: 31406563 Free PMC article.
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, Tan MCB, Brown RE, Nemunaitis J, Whitman E, Windham C, Lutzky J, Downey GF, Batty N, Amatruda T. Chesney J, et al. Among authors: amatruda t. Melanoma Res. 2018 Feb;28(1):44-51. doi: 10.1097/CMR.0000000000000399. Melanoma Res. 2018. PMID: 29176501 Clinical Trial.
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB. Kaufman HL, et al. Among authors: amatruda t. Nat Rev Clin Oncol. 2013 Oct;10(10):588-98. doi: 10.1038/nrclinonc.2013.153. Epub 2013 Aug 27. Nat Rev Clin Oncol. 2013. PMID: 23982524
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.
Dillman RO, Cornforth AN, Nistor GI, McClay EF, Amatruda TT, Depriest C. Dillman RO, et al. Among authors: amatruda tt. J Immunother Cancer. 2018 Mar 6;6(1):19. doi: 10.1186/s40425-018-0330-1. J Immunother Cancer. 2018. PMID: 29510745 Free PMC article. Clinical Trial.
Signal transduction by the formyl peptide receptor. Studies using chimeric receptors and site-directed mutagenesis define a novel domain for interaction with G-proteins.
Amatruda TT 3rd, Dragas-Graonic S, Holmes R, Perez HD. Amatruda TT 3rd, et al. J Biol Chem. 1995 Nov 24;270(47):28010-3. doi: 10.1074/jbc.270.47.28010. J Biol Chem. 1995. PMID: 7499283 Free article.
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M. Sperduto PW, et al. Among authors: amatruda t. Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1069-1077. doi: 10.1016/j.ijrobp.2017.03.030. Epub 2017 Mar 29. Int J Radiat Oncol Biol Phys. 2017. PMID: 28721890 Free PMC article.
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.
Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K, Nemunaitis J, Zloza A, Wolf M, Senzer NN. Kaufman HL, et al. Among authors: amatruda t. J Immunother Cancer. 2016 Mar 15;4:12. doi: 10.1186/s40425-016-0116-2. eCollection 2016. J Immunother Cancer. 2016. PMID: 26981242 Free PMC article.
52 results
Jump to page
Feedback